ME Therapeutics Holdings Inc. (CSE:METX)

Canada flag Canada · Delayed Price · Currency is CAD
3.040
+0.040 (1.33%)
Jul 21, 2026, 10:02 AM EST
Market Cap90.15M -39.1%
Revenue (ttm)n/a
Net Income-1.38M
EPS-0.05
Shares Out 30.05M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume200
Open3.040
Previous Close3.000
Day's Range3.040 - 3.040
52-Week Range0.790 - 8.000
Beta0.05
Analystsn/a
Price Targetn/a
Earnings DateNov 27, 2026

About ME Therapeutics Holdings

ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. The company’s lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. It also develops D094 and D099, which are small molecule myeloid targeted prodrug candidates to treat cancer; and myeloid targeting lipid nanoparticles (LNPS) formulations. ME Therapeutic... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Country Canada
Stock Exchange Canadian Securities Exchange
Ticker Symbol METX
Full Company Profile

Financial Performance

Financial Statements